Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital

Key Points

• The stock of Zura Bio (NASDAQ:ZURA) has been given a "buy" rating by Chardan Capital, with a target price of $10.00, indicating a potential upside of 481.40% from its current price.
• Despite a positive outlook from Chardan Capital, Oppenheimer has lowered its price target for Zura Bio from $19.00 to $17.00, maintaining an "outperform" rating.
• Zura Bio's stock recently increased by 8.2%, and the company reported earnings of ($0.17) per share, exceeding analysts' expectations.

Zura Bio (NASDAQ:ZURA - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $10.00 target price on the stock. Chardan Capital's target price would indicate a potential upside of 481.40% from the stock's current price.

Separately, Oppenheimer lowered their price target on Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a report on Friday, May 9th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $14.33.

Zura Bio Stock Up 8.2%

Shares of NASDAQ:ZURA opened at $1.72 on Friday. The business has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.32. The stock has a market cap of $117.61 million, a P/E ratio of -2.46 and a beta of -0.06. Zura Bio has a 52-week low of $0.97 and a 52-week high of $5.07.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Zura Bio

Hedge funds have recently bought and sold shares of the stock. Two Sigma Advisers LP acquired a new stake in Zura Bio in the 4th quarter valued at about $32,000. Savant Capital LLC raised its position in Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company's stock valued at $34,000 after purchasing an additional 21,249 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Zura Bio in the 4th quarter valued at about $35,000. XTX Topco Ltd acquired a new stake in Zura Bio in the 4th quarter valued at about $44,000. Finally, Wells Fargo & Company MN raised its position in Zura Bio by 68.6% in the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after purchasing an additional 9,379 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company's stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.